2022-11-17T12:26:48-06:00 2020-09-30 953309779 GURSEY SCHNEIDER LLP 1888 CENTURY PARK E 900 LOS ANGELES CA 90067 990 2019-10-01 954296919 INTERNATIONAL MYELOMA FOUNDATION INTE 8184877455 4400 COLDWATER CANYON AVE NO 300 STUDIO CITY CA 91604 YELAK BIRU PRESIDENT 8184877455 2022-11-11 1 NAZ AFSHAR P00441843 3105520960 2019 2022-09-23 18:48:47Z X X YELAK BIRU 4400 COLDWATER CANYON AVE SUITE 300 STUDIO CITY CA 91604 15223099 0 X WWW.MYELOMA.ORG X 1990 CA DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 18 17 51 3 0 0 20084695 14700757 72368 24801 165880 143969 -297325 -4868 20025618 14864659 370000 326667 0 0 5954445 5434244 0 0 1134318 13006481 8746533 19330926 14507444 694692 357215 18014619 17557878 9119429 7994379 8895190 9563499 X DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 0 0 6708262 326667 RESEARCH - THE INTERNATIONAL MYELOMA FOUNDATION (IMF) IS THE LEADER IN GLOBALLY COLLABORATIVE MYELOMA RESEARCH. IMF SUPPORTS LAB-BASED RESEARCH AND HAS AWARDED OVER 151 GRANTS TO TOP JUNIOR AND SENIOR RESEARCH SCIENTISTS SINCE 1995. IN ADDITION, IMF BRINGS TOGETHER THE WORLD'S LEADING EXPERTS IN THE MOST SUCCESSFUL AND UNIQUE WAY THROUGH THE INTERNATIONAL MYELOMA WORKING GROUP, WHICH IS PUBLISHING IN PRESTIGIOUS MEDICAL JOURNALS, CHARTING THE COURSE TO A CURE, MENTORING THE NEXT GENERATION OF INNOVATIVE INVESTIGATORS, AND IMPROVING LIVES THROUGH BETTER CARE. THE BLACK SWAN RESEARCH INITIATIVE IS A MULTINATIONAL CONSORTIUM OF LEADING MYELOMA EXPERTS WHO ARE HARNESSING NEW TECHNOLOGIES AND THE LATEST MYELOMA TREATMENTS TO FIND A PATHWAY TO A CURE. THE BLACK SWAN RESEARCH STRATEGY CAPITALIZES ON THE AVAILABILITY OF POTENT NOVEL THERAPIES AND THE ADVENT OF ULTRA-SENSITIVE TESTS TO MEASURE EXACTLY WHEN AND HOW THOSE THERAPIES ARE WORKING IN PATIENTS. THE BLACK SWAN RESEARCH INITIATIVE IS DEDICATED TO DEVELOPING NEW CURATIVE THERAPIES FOR MYELOMA. 1512591 EDUCATION AND AWARENESS - ALTHOUGH IT IS THE SECOND MOST COMMON BLOOD CANCER, MULTIPLE MYELOMA IS STILL A RELATIVELY UNKNOWN DISEASE. FOR MANY PATIENTS AND THEIR CAREGIVERS, IT IS AT DIAGNOSIS WHEN THEY FIRST HEARD THE WORD "MYELOMA". IMF RECOGNIZES THE NEED FOR COMPREHENSIVE EDUCATION PROGRAMS FOR BOTH THE PATIENT AND THE PHYSICIAN TO ENSURE THAT PATIENTS ARE DIAGNOSED CORRECTLY AND TREATED EFFECTIVELY. OUR LIBRARY OF MORE THAN 100 PUBLICATIONS FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, IS AVAILABLE FREE OF CHARGE. PUBLICATIONS ARE UPDATED ANNUALLY AND AVAILABLE IN MORE THAN 19 INTERNATIONAL LANGUAGES. THE IMF EMPOWERS PATIENTS AND THEIR CAREGIVERS TO JOIN HEALTHCARE PROVIDERS AS ACTIVE DECISION-MAKING PARTNERS, LEADING TO THE BEST POSSIBLE QUALITY OF LIFE FOR EACH INDIVIDUAL MYELOMA PATIENT. THE IMF PRODUCES COMPREHENSIVE BUT 'USER-FRIENDLY' INFORMATION FOR THE ENTIRE MYELOMA COMMUNITY. THE IMF'S PUBLICATIONS LIBRARY INCLUDES AN EXTENSIVE CATALOG OF BOOKLETS, TIP CARDS, ARTICLES, WEBINARS AND TELECONFERENCES, BLOGS, DIGITAL MEDIA AND INTERVIEWS, ALL WRITTEN, CREATED, AND PRODUCED BY THE IMF WITH OVERSIGHT BY ITS SCIENTIFIC ADVISORY COMMITTEE. THE IMF LIBRARY'S BROAD SCOPE INCLUDES INFORMATION ABOUT MYELOMA TREATMENT OPTIONS, CLINICAL TRIALS, AND QUALITY OF LIFE CONSIDERATIONS FOR PATIENTS AND PHYSICIANS. 735224 24801 SUPPORT GROUPS - THROUGH A GLOBAL COMMUNITY OF VOLUNTARY SUPPORT GROUPS, THE IMF SEEKS TO ENSURE THAT PATIENTS AND FAMILIES HAVE LOCAL ACCESS TO SUPPORT AND EDUCATION. THE IMF CURRENTLY SUPPORTS OVER 300 SUPPORT GROUPS WORLDWIDE. THE IMF OFFERS UNEQUALED WEBSITE CREATION AND HOSTING FOR LOCAL SUPPORT GROUPS, AND PROVIDED A UNIQUE OPPORTUNITY FOR SOME SUPPORT GROUP LEADERS TO ATTEND THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. THE 20TH ANNUAL SUPPORT GROUP LEADERS SUMMIT TOOK PLACE WITH OVER 100 LEADERS IN ATTENDANCE. THE SUPPORT GROUPS REPRESENTED AT THE SUMMIT SERVE MORE THAN 6,250 SUPPORT GROUP MEMBERS, EXTENDING THE SUMMIT'S REACH TO THOUSANDS OF MYELOMA PATIENTS AND FAMILY MEMBERS. TECHNOLOGY CONTINUES TO BE EMPHASIZED FOR SUPPORT GROUP LEADERS. DURING THE PANDEMIC, THE IMF TRANSITIONED MORE THAN 100 SUPPORT GROUPS TO VIRTUAL MONTHLY MEETINGS. THE IMF ALSO CONTINUED TO UPDATE ITS APP SPECIFICALLY DESIGNED FOR SUPPORT GROUP LEADERS WHICH OFFER MEETING AND EDUCATION MATERIALS ACCESSIBLE TO HELP BUILD EFFECTIVE COMMUNICATION WITH PATIENTS, CAREGIVERS AND FAMILY MEMBERS. 3830863 INTERNATIONAL - THE IMF GROWS ITS NETWORK OF HEALTH CARE PROFESSIONALS AROUND THE WORLD. KEY TEAM MEMBERS ORGANIZE PHYSICIAN AS WELL AS PATIENT MEETINGS IN ORDER TO PROVIDE EDUCATION ABOUT THE LATEST DEVELOPMENTS IN THE FIELD OF MULTIPLE MYELOMA.PATIENT AND FAMILY SEMINARS: THE IMF'S PATIENT AND FAMILY SEMINARS PRESENT VITAL INFORMATION ABOUT NEW TREATMENTS AND CLINICAL TRIALS, PROVIDE TIME WITH MYELOMA SPECIALISTS IN INTIMATE SETTINGS, AND ALLOW PARTICIPANTS TO SHARE THEIR PERSONAL EXPERIENCES AND SUPPORT. PREMIER MYELOMA EXPERTS VOLUNTEER THEIR TIME TO THE SEMINARS, TO EMPOWER PATIENTS AND THEIR FAMILIES TO MAKE EDUCATED TREATMENT CHOICES TAILORED TO THEIR NEEDS. IN ADDITION TO PATIENT AND FAMILY SEMINARS, THE IMF FACILITATES REGIONAL COMMUNITY WORKSHOPS, WHICH SERVE AS CONDENSED SEMINARS IN SMALLER CITIES TO EXPAND THE REACH OF IMF PROGRAMS AND UP-TO-DATE INFORMATION ON MYELOMA CARE, SUPPORT AND TREATMENT TO A WIDER AUDIENCE AT NO CHARGE.NURSE - THE IMF NURSE LEADERSHIP BOARD IS A PROFESSIONAL PARTNERSHIP REPRESENTING NURSE EXPERTS CARING FOR MYELOMA PATIENTS AT LEADING MEDICAL CENTERS. FOUNDED IN NOVEMBER 2006, THE NLB HAS PROVEN TO BE INVALUABLE TO THE MYELOMA COMMUNITY AS A PLATFORM THAT BOLSTERS NURSING EDUCATION, CLINICAL CARE EXPERIENCE EXCHANGE, AND PATIENT KNOWLEDGE AND EMPOWERMENT IN AN EFFORT TO OPTIMIZE OUTCOMES FOR PATIENTS WITH MYELOMA. THIS BOARD OF EXPERIENCED MYELOMA NURSES HAS MADE GREAT STRIDES IN IMPROVING THE NURSING CARE AND SELF-CARE OF MYELOMA PATIENTS SINCE ITS INCEPTION.CLINICAL MEETINGS - IMF TEAM MEMBERS ORGANIZE CLINICAL MEETINGS, BRINGING TOGETHER THE WORLD'S LEADING MYELOMA EXPERTS, TO FORM A COALITION THAT WILL WORK COLLABORATIVELY ON MYELOMA-RELATED PROJECTS AND AVOID DUPLICATION OF EFFORTS AND DILUTION OF VALUABLE RESOURCES. THESE COALITIONS PROMOTE EXCELLENCE IN CLINICAL PRACTICE, RESEARCH AND EDUCATION AND CME-ACCREDITED MEDICAL EDUCATION PROGRAMS. THIS PAST YEAR ALSO INCLUDED EDUCATION TO THE COMMUNITY PHYSICIAN AND NURSE VIA ONLINE AND LIVE INSTRUCTION.ADVOCACY - THE IMF IS DEDICATED TO CREATING A GLOBAL COMMUNITY THAT SUPPORTS THE WIDE-RANGING NEEDS OF ALL AFFECTED BY MYELOMA. THE IMF ADVOCATES ON BEHALF OF THOSE AFFECTED BY MULTIPLE MYELOMA FOR AN INCREASE IN ACCESSIBILITY OF HIGH-QUALITY DIAGNOSTICS AND TREATMENTS, FOR FUNDING OF MYELOMA-RELATED RESEARCH, AND FOR AN END TO INSURANCE COVERAGE DISPARITIES FOR TREATMENT. THE IMF INCLUDES THE ENTIRE MYELOMA COMMUNITY IN THESE EFFORTS AND CONTINUES TO EXPAND ITS COMMITMENT TO EMPOWERING PATIENTS, FAMILIES, AND FRIENDS TO ADVOCATE ON BEHALF OF PATIENT RIGHTS.INFOLINE - THE IMF'S TOLL-FREE INFORMATION TELEPHONE LINE PROVIDES LIFE-SAVING AND LIFE-CHANGING MYELOMA TREATMENT AND MANAGEMENT SUPPORT FROM COMPASSIONATE, HIGHLY TRAINED SPECIALISTS. AS NEW TREATMENT OPTIONS ARE GAINING ATTENTION AND USE IN MULTIPLE MYELOMA, ANSWERING QUESTIONS ABOUT MYELOMA, ITS TREATMENT, DRUG SIDE EFFECTS, OPTIONS FOR POSSIBLE CLINICAL TRIALS OTHER HEALTH CONCERNS, AND WHERE TO FIND LOCAL SUPPORT IS MORE IMPORTANT THAN EVER.WEBSITE - THE IMF WEBSITE IS THE LEADING RESOURCE FOR MYELOMA-RELATED CONTENT AND THE MOST COMPLETE SOURCE OF ANSWERS FROM THE MANY QUESTIONS ASKED BY THOSE NEWLY DIAGNOSED TO THOSE MANAGING MYELOMA FOR MANY YEARS. THE WEBSITE CONSIDERS PATIENTS, CAREGIVERS, FAMILY MEMBERS, AND HEALTHCARE PROFESSIONALS. INFORMATION IS AVAILABLE IN MULTIPLE LANGUAGES AND FOCUS IS ON THE IMF'S RESEARCH, EDUCATION, SUPPORT AND ADVOCACY INITIATIVES.MYELOMA TODAY - MYELOMA TODAY IS A QUARTERLY NEWSLETTER AND THE GO-TO RESOURCE FOR THE MYELOMA COMMUNITY TO LEARN ABOUT THE LATEST ADVANCES IN MYELOMA TREATMENT, RESEARCH AND QUALITY OF LIFE ISSUES. IT IS PROVIDED FREE OF CHARGE.INFORMATIONAL MAILINGS - THE INFOPACK IS MADE UP OF A SELECTION OF THE IMF'S PUBLICATIONS AND IS DESIGNED TO PROVIDE NEWLY DIAGNOSED PATIENTS AND THEIR FAMILIES WITH A COMPLETE UNDERSTANDING OF THE DISEASE AND CARE. THE INFO PACK CONTAINS INFORMATIVE MATERIALS FREE OF CHARGE IN 19 LANGUAGES. 3830863 12786940 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 1 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 38 0 1 51 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 18 17 1 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC OH OK OR PA RI SC TN UT VA WA WV WI X X X JENNIFER SCARNE 8184877455 12650 RIVERSIDE DRIVE 206 NORTH HOLLYWOOD CA 91607 DR BRIAN DURIE CHAIRMAN 1.00 X 0 0 0 SUSAN DURIE PRESIDENT 40.00 X X 251426 0 32729 BENSON KLEIN DIRECTOR 1.00 X 0 0 0 DR ROBERT A KYLE DIRECTOR 1.00 X 0 0 0 DR EDITH MITCHELL DIRECTOR 1.00 X 0 0 0 CHARLES NEWMAN DIRECTOR 1.00 X 0 0 0 MATTHEW ROBINSON DIRECTOR 1.00 X 0 0 0 E MICHAEL D SCOTT DIRECTOR 1.00 X 0 0 0 LORAINE BOYLE DIRECTOR 1.00 X 0 0 0 DR VINCENT RAJKUMAR DIRECTOR 1.00 X 0 0 0 DR MARIO BOCCADORO DIRECTOR 1.00 X 0 0 0 ANDREW KUZNESKI III DIRECTOR 1.00 X 0 0 0 DR HEINZ LUDWIG DIRECTOR 1.00 X 0 0 0 CHRISTINE BATTISTINI DIRECTOR 1.00 X 0 0 0 YELAK BIRU DIRECTOR 1.00 X 0 0 0 JASON KATZ DIRECTOR 1.00 X 0 0 0 GEORGE T HAYUM DIRECTOR 1.00 X 0 0 0 MARTINE ELIAS DIRECTOR 1.00 X 0 0 0 JENNIFER SCARNE CFO/COO 40.00 X 269600 0 20797 DIANE MORAN STRATEGIC PLANNER 40.00 X 400000 0 16369 LISA PAIK SENIOR VICE PRESIDENT 40.00 X 203000 0 24266 JOSEPH MIKHAEL CHIEF MEDICAL OFFICER 40.00 X 450000 0 18174 PETER ANTON VICE PRESIDENT, MARKETING 40.00 X 190133 0 29431 LYNN GREEN SENIOR VICE PRESIDENT, PHI 40.00 X 199000 0 5983 1963159 0 147749 18 0 1 0 DAN NAVID SIRA SILA 20/46 SOI 97 HUA HIN TH 77110 INTERNATIONAL GLOBAL STRATEGY 208000 MIMI CHOON-QUINONES IM CHRUZ 17 ARISDORF BASEL LAND SZ 4422 INTERNATIONAL ADVOCACY, ACCESS, POLICY, 195000 DRINKER BIDDLE & REATH LLP ONE LOGAN SQUARE STE 2000 PHILIDELPHIA PA 19103 ADVOCACY CONSULTING SERVICES 121500 3 14700757 14700757 SUPPORT GROUP 611710 24801 24801 24801 143969 143969 353572 358440 -4868 -4868 14864659 24801 0 139101 130000 130000 196667 196667 503719 404231 37033 62455 4930525 3956711 362489 611325 102094 90034 4078 7982 53666 46468 3335 3863 1409703 1359130 50573 481875 453234 7061 21580 226301 147574 10207 68520 332757 226477 42464 63816 657413 637930 13163 6320 1483670 1395901 83327 4442 215422 186659 14242 14521 78000 69611 3652 4737 PRINTING & PUBLICATIONS 3302451 3288496 13955 POSTAGE & SHIPPING 206509 49563 1308 155638 TELEPHONE 117564 101565 2854 13145 DUES & SUBSCRIPTIONS 34116 20325 13791 44992 26364 973 17655 14507444 12786940 586186 1134318 1329030 912977 2624490 3259871 215001 5710832 2946166 1038027 789875 1008863 604988 624404 403875 6551634 8904793 136202 125320 18014619 17557878 2583802 210909 6457610 7708732 78017 74738 9119429 7994379 X 8708329 9487921 186861 75578 8895190 9563499 18014619 17557878 357215 311095 0 X 0 1 X 1 0 X 11394264 9690465 11470224 19852188 14700757 67107898 11394264 9690465 11470224 19852188 14700757 67107898 31202472 35905426 197754 170097 134827 371600 459595 1333873 68441771 193795 0.52460 0.47930 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 90046 166747 256793 14465652 14722445 886122 221531 0 0 902008 946948 1000000 886122 3735078 5602617 202131 234619 245639 256793 939182 225502 236737 250000 221531 933770 1400655 39381 43144 50192 90046 222763 13246 5080 8166 795210 526448 268762 200407 73460 126947 403875 ANNUITY PYMT LIABILITY 74738 74738 X 15175754 311095 311095 14864659 0 14864659 14722445 215001 215001 14507444 0 14507444 PART X, LINE 2: MANAGEMENT HAS ANALYZED THE TAX POSITIONS TAKEN BY THE ENTITY AND HAS CONCLUDED THAT AS OF SEPTEMBER 30, 2020, THERE WERE NO UNCERTAIN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN. ACCORDINGLY, NO INTEREST OR PENALTIES RELATED TO UNCERTAIN TAX POSITIONS WERE ACCRUED IN THE ACCOMPANYING FINANCIAL STATEMENTS. THE ENTITY IS SUBJECT TO AUDITS BY TAXING JURISDICTIONS, HOWEVER, NO AUDITS FOR ANY TAX PERIODS ARE CURRENTLY IN PROGRESS. MANAGEMENT BELIEVES THAT THE ENTITY IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS FOR YEARS ENDED ON OR PRIOR TO SEPTEMBER 30, 2017 UNDER FEDERAL AND CALIFORNIA TAX JURISDICTIONS. PART XII, LINE 2D - OTHER ADJUSTMENTS: WAGE EXPENSE REDUCED FOR EMPLOYEE RETENTION CREDIT 1 EUROPE 1 1 PROGRAM SERVICES AWARDED RESEARCH GRANTS, CONDUCTED RESEARCH PROJECTS, PATIENT & FAMILY SEMINARS, AND PATIENT AND PHYSICIAN REGIONAL COMMUNITY WORKSHOPS. 2690694 EAST ASIA AND THE PACIFIC 1 1 PROGRAM SERVICES AWARDED RESEARCH GRANTS, CONDUCTED RESEARCH PROJECTS, PATIENT & FAMILY SEMINARS, PATIENT AND PHYSICIAN REGIONAL COMMUNITY WORKSHOPS. 1266998 NORTH AMERICA - CANADA PROGRAM SERVICES CONDUCTED RESEARCH PROJECTS, PATIENT EDUCATION. 165280 MIDDLE EAST - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, PROGRAM SERVICES CONDUCTED PATIENT & FAMILY SEMINARS. 97794 SOUTH AMERICA PROGRAM SERVICES AWARDED GRANTS AND CONDUCTED RESEARCH PROJECTS. 36195 2 2 0 0 2 2 4256961 0 4256961 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM TARGETING AXL, A PUTATIVE DORMANCY REGULATORY IN MULTIPLE MYELOMA 33333 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM UNRAVELING THE BALANCE OF TOLERANCE AND IMMUNOGENICITY OF MULTIPLE MYELOMA CELLS 16667 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SINGLE CELL SEQUENCING TO DISCOVER TUMOR-ASSOCIATED CHANGES IN THE BONE MICROENVIRONMENT OF MYELOMA PATIENTS: IDENTIFICATION OF PROGNOSTIC MARKERS AND NOVEL THERAPEUTIC TARGETS 26667 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, DISSECTING THE STRUCTURAL AND FUNCTIONAL HETEROGENEITY OF TERMINAL EFFECTOR CD8+T CELLS FROM MGUS AND NEWLY DIAGNOSED MM PATIENTS IN ORDER TO IDENTIFY THERAPEUTIC TARGETS AND UNLOCK THEIR ANTI-MYELOMA POTENTIAL 16667 EUROPE (INCLUDING ICELAND & GREENLAND) FUNCTIONAL CHARACTERIZATIONS OF MONOCIONAL IMMUNOGLOBULINS FROM ANTIGEN DRIVEN MGUS & MYELOMA 53333 EUROPE (INCLUDING ICELAND & GREENLAND) A "CLICK READY" CEREBLON E3 LIGASE MODULATION DRUG LIBRARY FOR FAST IN VIVO EVALUATION IN MULTIPLE MYELOMA MOUSE MODELS 33333 EUROPE (INCLUDING ICELAND & GREENLAND) MANIPULATING ENDOPLASMIC RETICULUM HOMEOSTASIS AND SECRETORY CAPACITY AGAINST SYSTEMIC AL AMYLOIDOSIS 16667 7 0 0 0 0 0 0 PART I, LINE 2: FOR RESEARCH GRANT FUNDS, REPORTS ARE PROVIDED AS PART OF THE REQUIRED GRANT COMPLIANCE PROCESS BUILT INTO THE GRANT AGREEMENT. PART III ACCOUNTING METHOD: GALA 353572 353572 358440 353572 353572 358440 358440 -4868 N/A 1 DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02115 042263040 IRC SEC 501(C)(3) 16667 OVERCOMING RESISTANCE TO PHARMACOLOGICAL DEGRADERS OF MYELOMA ONCOPROTEINS MICHIGAN STATE UNIVERSITY 426 AUDITORIUM ROAD EAST LANSING MI 48824 386005984 IRC SEC 501(C)(3) 26667 TARGETING C-MYC DEGRADATION TO TREAT MULTIPLE MYELOMA WAKE FOREST UNIVERSITY HEALTH SCIENCES 1834 WAKE FOREST RD WINSTONSALEM NC 27109 223849199 IRC SEC 501(C)(3) 53333 LEVERAGING POLYAMINE DEPENDENCY FOR TREATMENT OF DRUG RESISTANT MULTIPLE MYELOMAS MEMORIAL SLOAN KETTERING CANCER CENTRE 1275 YORK AVE NEW YORK NY 10065 131924236 IRC SEC 501(C)(3) 33333 DECIPHERING THE IMPACT OF MELPHALAN ON SECONDARY MALIGNANCY IN MULTIPLE MYELOMA 4 PART I, LINE 2: USE OF GRANT FUNDS ARE MONITORED ACCORDING TO TERMS AND PROCEDURES DEFINED IN THE GRANT AGREEMENT. 1 X 0 0 0 0 0 0 0 1 0 SUSAN DURIE PRESIDENT 231426 0 20000 0 0 0 0 0 32729 0 284155 0 0 0 JENNIFER SCARNE CFO/COO 249600 0 20000 0 0 0 0 0 20797 0 290397 0 0 0 DIANE MORAN STRATEGIC PLANNER 375000 0 25000 0 0 0 0 0 16369 0 416369 0 0 0 LISA PAIK SENIOR VICE PRESIDENT 200000 0 3000 0 0 0 0 0 24266 0 227266 0 0 0 JOSEPH MIKHAEL CHIEF MEDICAL OFFICER 450000 0 0 0 0 0 0 0 18174 0 468174 0 0 0 PETER ANTON VICE PRESIDENT, MARKETING 180133 0 10000 0 0 0 0 0 29431 0 219564 0 0 0 LYNN GREEN SENIOR VICE PRESIDENT, PHI 199000 0 0 0 0 0 5983 0 0 0 204983 0 0 0 PART I, LINE 7 BONUSES PAID: SUSAN LAVITT NOVIS - $20,000 DIANE MORAN - $25,000 JENNIFER SCARNE - $20,000 LISA PAIK - $3,000 PETER ANTON - $10,000 FORM 990, PART VII LINE 5 CHAIRMAN, DR. BRIAN DURIE, WAS COMPENSATED $192,000 FROM THE DURIE GROUP FOR SERVICES RENDERED TO THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 2 SUSAN NOVIS, PRESIDENT AND DR. BRIAN DURIE, CHAIRMAN ARE HUSBAND AND WIFE. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO THE FINANCE COMMITTEE OF THE BOARD FOR REVIEW PRIOR TO FILING THE TAX RETURN. FORM 990, PART VI, SECTION B, LINE 12C THIS PROCEDURE IS PERFORMED ANNUALLY AT THE ORGANIZATION'S BOARD OF DIRECTORS RETREAT. FORM 990, PART VI, SECTION B, LINE 15 FOR KEY EMPLOYEES, A REVIEW OF COMPARABLE COMPENSATION DATA IS REVIEWED BY THE FINANCE COMMITTEE. MEMBERS OF THE FINANCE COMMITTEE APPROVE OF THE COMPENSATION PACKAGE AND WOULD NOT HAVE A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT ISSUE. THE DECISION IS DISCUSSED AND RECORDED IN THE EXECUTIVE COMMITEE AND FINANCE COMMITTEE BOARD OF DIRECTOR MEETING MINUTES. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS OF THE ORGANIZATION ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE, AND UPON REQUEST. THESE DOCUMENTS HAVE BEEN PROVIDED TO A THIRD PARTY WEBSITE "CHARITY NAVIGATOR: YOUR GUIDE TO INTELLIGENT GIVING." FORM 990 PART IX LINE 6 & 7, PART X LINE 3, AND SCH D PART XIII 2D INTERNATIONAL MYELOMA FOUNDATION IS AMENDING THE FORM 990 TO REFLECT EMPLOYEE RETENTION CREDIT (ERC) CLAIMED. THE ORGANIZATION AMENDED ITS FORM 941 FOR THE 2ND AND 3RD QUARTERS OF 2019 TO CLAIM $215,001 OF TAX CREDITS. PART IX LINE 6 & 7 : SALARIES AND WAGES ARE BEING REDUCED BY A TOTAL OF $215,001. PART X LINE 3: A CORRESPONDING GRANT RECEIVABLE OF $215,001 IS BEING REPORTED ON THE BALANCE SHEET. SCH D PART XIII 2D: $215,001 RECONCILING ITEM WITH THE AUDITED FINANCIAL STATEMENTS